Free Trial
NASDAQ:PSTV

Plus Therapeutics Q2 2026 Earnings Results & Report

Plus Therapeutics logo
$0.95 +0.18 (+23.32%)
As of 11/13/2026

Plus Therapeutics missed analyst expectations on both earnings and revenue in its Q2 2026 results, released August 13, 2026. The company reported EPS of -$1.31 versus the -$0.88 consensus estimate, while revenue of $411 thousand fell short of the $1.11 million estimate by $702 thousand.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes
Conference Call Date
Conference Call
7:00 AM ET

Plus Therapeutics EPS Results

Actual EPS
-$1.31
Consensus EPS
-$0.88
Beat/Miss
Missed by -$0.43
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Plus Therapeutics Revenue Results

Actual Revenue
$411 thousand
Expected Revenue
$1.11 million
Beat/Miss
Missed by -$702.00 thousand
YoY Revenue Growth
N/A

Plus Therapeutics Q2 2026 Earnings FAQ

Plus Therapeutics (NASDAQ:PSTV) reported earnings of -$1.31 per share for Q2 2026, missing the consensus estimate of -$0.88. The report was announced on Thursday, August 13, 2026.

Plus Therapeutics reported revenue of $411 thousand for Q2 2026, against a consensus estimate of $1.11 million.

Plus Therapeutics Earnings Headlines

Plus Therapeutics (NASDAQ:PSTV) Stock Falls 4.1% - What's Next?
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
See More Plus Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Plus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Plus Therapeutics and other key companies, straight to your email.

About Plus Therapeutics

Plus Therapeutics (NASDAQ:PSTV) is a clinical-stage biotechnology company developing targeted treatments and diagnostic tools for cancers affecting the central nervous system. Its work includes radiopharmaceutical therapies designed to deliver radiation to tumors while limiting exposure to surrounding healthy tissue.

The company’s lead therapeutic program is Rhenium-186 NanoLiposome (RNL), an investigational treatment being studied for cancers including recurrent glioblastoma and leptomeningeal metastases. Plus Therapeutics also develops CNSide, a diagnostic platform intended to help detect and monitor cancer cells in cerebrospinal fluid.

Previously known as Cytori Therapeutics, the company adopted the Plus Therapeutics name in 2019. It is based in the United States and focuses its development programs on cancers of the brain and central nervous system.

View Plus Therapeutics Profile